Pulmonary Fibrotic Diseases This review covers fibrotic pulmonary diseases. Although
idiopathic pulmonary fibrosis is very common, the review focuses mainly on fibrotic diseases …

Patients with certain types of fibrosing interstitial lung disease (ILD) are at risk of developing
a progressive phenotype characterised by self-sustaining fibrosis, decline in lung function …

Pirfenidone (PFD) is a pharmacological compound with therapeutic efficacy in idiopathic
pulmonary fibrosis. It has been chiefly characterized as an antifibrotic agent, although it was …

A proportion of patients with certain types of interstitial lung disease (ILD), including chronic
hypersensitivity pneumonitis and ILDs associated with autoimmune diseases, develop a …

Background INCREASE was a randomised, placebo-controlled, phase 3 trial that evaluated
inhaled treprostinil in patients with interstitial lung disease (ILD) and associated pulmonary …

Rationale: Respiratory-related hospitalizations of patients with idiopathic pulmonary fibrosis
(IPF) are more frequent than those for acute IPF exacerbations and are associated with poor …

Background Childhood interstitial lung disease (ILD) comprises a spectrum of rare ILDs
affecting infants, children and adolescents. Nintedanib is a licensed treatment for pulmonary …

Importance Alteration in lung microbes is associated with disease progression in idiopathic
pulmonary fibrosis. Objective To assess the effect of antimicrobial therapy on clinical …

Previous phase I studies demonstrated safety and some beneficial effects of mesenchymal
stem cells (MSCs) in patients with mild to moderate idiopathic pulmonary fibrosis (IPF). The …

Interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF) have an array
of immunomodulatory treatment options compared with IPF, due to their inflammatory …